Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biyi Clinical Sciences, also known as Jiangsu Biyi Biological Technology, is a comprehensive Clinical Research Organization (CRO) headquartered in the Suzhou Industrial Park, China. Founded in 2017, the company provides a "one-stop" service platform for drug discovery and development, including clinical operations, Site Management Organization (SMO) services, bioanalytical testing, and regulatory affairs. Biyi specializes in bioequivalence (BE) studies and Phase I-III clinical trials, supporting the development and registration of both generic and innovative drugs. The company operates several specialized subsidiaries and research institutes, maintaining a strong focus on clinical pharmacology and pharmaceutical technology innovation to serve its pharmaceutical partners in the Chinese market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangsu BiYi Biotechnology.